1. FDA. November2020.Enhancing the diversity of clinical trial populations — eligibility criteria enrollment practices and trial designs guidance for industry.
2. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
3. Physiological‐ based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms;El‐Khateeb E;Biopharm Drug Dispos,2020
4. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA's office of clinical pharmacology;Zhang X;J Clin Pharmacol,2020
5. FDA. August2018.Physiologically based pharmacokinetic analyses–format and content guidance for industry. Available athttps://wwwfdagov/regulatory‐information/search‐fda‐guidance‐documents/physiologically‐based‐pharmacokinetic‐analyses‐format‐and‐content‐guidance‐industry. Accessed January 2021.